News & Events
26 January 2012 Update on 3D Culture Collaboration with InSphero
24 January 2012 AACR Annual Meeting 2012
19 January 2012 BioTrinity 2012
19 January 2012 BIO-Europe Spring 2012
19 January 2012 European Partnering & Investment Conference
17 January 2012 Biosimulation Scientist
11 November 2011 Physiomics to present on R&D Developments at the 2011 EORTC-NCI-AACR symposium on “Molecular targets and Cancer Therapeutics”
Virtual Tumour Platform
Physiomics' Virtual Tumour platform predicts optimal drug dosing, scheduling and combinations.
Physiomics helps pharmaceutical and biotechnology companies to determine optimal doses, schedules and combinations for their pre-clinical oncology candidates.
Virtual Tumour provides the following key benefits:
Improve success rates for oncology candidates entering clinical studies, by increasing efficacy
Reduce the time taken to do proof-of-principle
studies
Reduce the cost of xenograft study programmes
(fewer experiments needed)
Provide regulatory agencies with a rationale for the design of a clinical study programme
